NCT04920708 2026-04-14
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT04553133 2026-04-13
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT04650581 2026-04-13
FINER
Canadian Cancer Trials Group
Phase 3 Active not recruiting
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT05038735 2026-04-08
EPIK-B5
Novartis
Phase 3 Active not recruiting
NCT06764186 2026-04-08
CAPItana
AstraZeneca
Phase 3 Active not recruiting
NCT04544189 2026-04-02
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT04851613 2026-04-02
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Laekna Limited
Phase 3 Active not recruiting
NCT05161195 2026-04-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
NCT05307705 2026-03-27
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06635447 2026-03-27
CAPItrue
AstraZeneca
Phase 3 Active not recruiting
NCT04576455 2026-03-20
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Active not recruiting